Opendata, web and dolomites

Droplet Microarray SIGNED

Miniaturized System for Screening of Primary Cells based on Droplet Microarray

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Droplet Microarray project word cloud

Explore the words cloud of the Droplet Microarray project. It provides you a very rough idea of what is the project "Droplet Microarray" about.

167m    ec    read    experiments    performing    reduce    patient    context    consumption    individual    slides    technologies    scarce    incubator    labcyte    therapeutic    direct    reagents    society    medical    therapies    cells    model    37    biological    integrates    companies    mass    perform    microplates    personalized    apparatus    nano    human    mainly    optimal    treatment    screening    generate    precision    replacing    precious    inevitably    screenings    stem    time    alternative    life    sales    scarcity    impossible    tumor    nanoliter    liquid    assays    dispenser    discovery    larger    extremely    dispendix    revenues    business    2025    b2b    current    selling    hardly    maximized    microtiter    clinical    aquarray    plates    cartridge    market    miniaturization    employ    dma    drug    limits    disruptive    relevance    throughput    clinicians    medicine    circulating    innovation    primary    capturing    cell    possibility    animal    tests    dispensers    types    healthy    physiology    models    science    basic   

Project "Droplet Microarray" data sheet

The following table provides information about the project.

Coordinator
AQUARRAY GMBH 

Organization address
address: HERMANN-VON-HELMHOLTZ-PLATZ 1
city: EGGENSTEIN-LEOPOLDSHAFEN
postcode: 76344
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙499˙750 €
 EC max contribution 1˙749˙825 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2022-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AQUARRAY GMBH DE (EGGENSTEIN-LEOPOLDSHAFEN) coordinator 1˙749˙825.00

Map

 Project objective

Current cell screening systems based on microtiter plates are mainly used to perform drug discovery experiments. However, performing a larger number of therapeutic tests on patient derived (primary) cells is yet impossible due to the high consumption of reagents and cells when using microplates. In the clinical context, personalized drug screenings for optimal medical treatment are not possible due to the scarcity of precious primary cells. In pre-clinical drug discovery, the extremely high cost of primary cells limits the innovation potential as researchers hardly have access to screening models which are relevant for human physiology. The possibility to use scarce cell types like primary cells or stem cells therefore is the future of basic life science research, drug discovery (replacing animal models) as well as personalized medicine applications (individual precision therapies) and will have significant impact for a healthy society. Further miniaturization of current assays would inevitably allow the wide use of scarce cell types and at the same time reduce costs, increase throughput, and increase biological relevance of screening results. DMA allows researchers and clinicians to perform meaningful experiments with primary cells and circulating tumor cells – alternative technologies hardly work with low cell numbers. EC funding Phase 2 will allow Aquarray to mass produce its offer – the DMA Cartridge and also the disruptive Cell Screening System that integrates the DMA Cartridge with a nanoliter dispenser, an incubator and a read-out apparatus. Aquarray’s disruptive business model will employ a B2B direct sales of the DMA Slides and the Screening System, and at the same time sales can be maximized through partnerships with companies selling liquid nano-dispensers such as Dispendix and Labcyte. We are expected to generate €167M revenues by 2025 capturing 9.37% of the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DROPLET MICROARRAY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DROPLET MICROARRAY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

SPANAR (2019)

Safe Perception And Navigation for Autonomous Robots

Read More  

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More